Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine

Hidenori Matsunaga, Hidefumi Takeuchi, Yuichiro Oba, Satoshi Fujimi, Tomoyuki Honda, Keizo Tomonaga

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 C; males: 37.1 C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination.

Original languageEnglish
Article number177
JournalVaccines
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2022

Keywords

  • Anti-SARS-CoV-2 spike antibody
  • BNT162b2 vaccine
  • Delta variant
  • Sex-associated differences
  • Third antigen stimulation

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine'. Together they form a unique fingerprint.

Cite this